Robert Cascella
Robert Cascella's purchase track record
How the stock did after each of Robert Cascella's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/12/2024 | STIM | $75K | +56.8% | +496.0% | -1.3% |
| 8/14/2024 | STIM | $100K | -26.5% | +378.9% | +10.9% |
| 6/6/2024 | STIM | $103K | -61.4% | -41.4% | +13.5% |
| 8/16/2023 | KRMD | $50K | -15.9% | -12.0% | +13.5% |
| 11/22/2021 | STIM | $61K | -29.2% | -39.9% | -15.1% |
| 8/30/2021 | STIM | $101K | -38.7% | -48.9% | -3.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Celestica noted in recent analyst optimism and stock picks. Recent media coverage has placed Celestica in several analyst and stock‑selection pieces. One article notes that Wall Street analysts hold an optimistic outlook, reflected in an average price target of $473.91. Another comparison with SpaceX highlights Celestica’s position in the aerospace sector. The stock is currently trading near a long‑standing support level, with momentum indicators showing modest weakness.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
STIM shifts focus from devices to psychedelic infrastructure. Neuronetics announced it is moving away from solely manufacturing its TMS device and is building a platform to support psychedelic therapies. The change aims to broaden the company's role in the emerging mental-health market. The stock is currently trading near its $1.19 support level and has an RSI of 25.4, indicating a low momentum environment.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Mirion Shares Rise Amid Nuclear Sector Momentum. Mirion Technologies stock has climbed recently, partly driven by broader optimism in the nuclear sector following TVA's first small modular reactor construction permit. Analysts currently hold an average price target of $24.00 for the shares. The company's valuation remains high relative to its earnings, with a trailing P/E of 164.6.
Transaction History
| KRMD | ▲ Buy | Grant | 5,119 | $15K | 10/1/2026 | View on chart |
| CLS | ▲ Buy | Option Exercise | 52 | $0 | 9/30/2026 | View on chart |
| CLS | ▼ Sell | Tax Withholding | 6 | $2K | 9/30/2026 | View on chart |
| KRMD | ▲ Buy | Grant | 3,571 | $15K | 7/1/2026 | View on chart |
| CLS | ▲ Buy | Option Exercise | 84 | $0 | 6/30/2026 | View on chart |
| CLS | ▼ Sell | Tax Withholding | 5 | $2K | 6/30/2026 | View on chart |
| STIM | ▲ Buy | Grant | 36,250 | $0 | 5/28/2026 | View on chart |
| MIR | ▲ Buy | Grant | 7,383 | $0 | 5/13/2026 | View on chart |
| KRMD | ▲ Buy | Grant | 3,472 | $15K | 4/1/2026 | View on chart |
| CLS | ▲ Buy | Option Exercise | 156 | $0 | 3/31/2026 | View on chart |
| CLS | ▼ Sell | Tax Withholding | 9 | $2K | 3/31/2026 | View on chart |
| KRMD | ▲ Buy | Grant | 2,581 | $15K | 1/2/2026 | View on chart |
| STIM | ▲ Buy | Grant | 10,531 | $0 | 10/20/2025 | View on chart |
| KRMD | ▲ Buy | Grant | 3,916 | $15K | 10/2/2025 | View on chart |
| KRMD | ▲ Buy | Grant | 4,189 | $15K | 7/2/2025 | View on chart |
| STIM | ▲ Buy | Grant | 36,250 | — | 5/22/2025 | View on chart |
| MIR | ▲ Buy | Grant | 7,977 | $0 | 5/15/2025 | View on chart |
| KRMD | ▲ Buy | Grant | 5,870 | $15K | 4/2/2025 | View on chart |
| STIM | ▼ Sell | Other | 88,888 | $200K | 2/7/2025 | View on chart |
| KRMD | ▲ Buy | Grant | 3,937 | $15K | 1/3/2025 | View on chart |
| KRMD | ▲ Buy | Grant | 5,454 | $15K | 10/1/2024 | View on chart |
| STIM | ▲ Buy | Open Market | 100,000 | $75K | 9/12/2024 | View on chart |
| STIM | ▲ Buy | Open Market | 4,000 | $5K | 8/19/2024 | View on chart |
| STIM | ▲ Buy | Open Market | 35,000 | $37K | 8/16/2024 | View on chart |
| STIM | ▲ Buy | Open Market | 35,000 | $31K | 8/15/2024 | View on chart |
| STIM | ▲ Buy | Open Market | 35,000 | $28K | 8/14/2024 | View on chart |
| KRMD | ▲ Buy | Grant | 5,545 | $15K | 7/11/2024 | View on chart |
| STIM | ▲ Buy | Open Market | 50,000 | $103K | 6/6/2024 | View on chart |
| MIR | ▲ Buy | Grant | 13,500 | $0 | 6/4/2024 | View on chart |
| STIM | ▲ Buy | Grant | 31,250 | — | 5/30/2024 | View on chart |
| KRMD | ▲ Buy | Grant | 6,329 | $15K | 3/31/2024 | View on chart |
| KRMD | ▲ Buy | Grant | 6,329 | $15K | 12/31/2023 | View on chart |
| KRMD | ▲ Buy | Grant | 5,484 | $15K | 9/30/2023 | View on chart |
| KRMD | ▲ Buy | Open Market | 19,000 | $50K | 8/16/2023 | View on chart |
| STIM | ▲ Buy | Grant | 28,500 | $52K | 8/10/2023 | View on chart |
| KRMD | ▲ Buy | Grant | 4,310 | $15K | 6/30/2023 | View on chart |
| MIR | ▲ Buy | Grant | 11,850 | $0 | 6/6/2023 | View on chart |
| STIM | ▲ Buy | Grant | 45,455 | — | 5/25/2023 | View on chart |
| KRMD | ▲ Buy | Grant | 3,521 | $15K | 3/31/2023 | View on chart |
| KRMD | ▲ Buy | Grant | 4,273 | $15K | 12/31/2022 | View on chart |
| KRMD | ▲ Buy | Grant | 6,681 | $15K | 9/30/2022 | View on chart |
| KRMD | ▲ Buy | Grant | 3,693 | $9K | 6/30/2022 | View on chart |
| MIR | ▲ Buy | Grant | 14,274 | $0 | 6/15/2022 | View on chart |
| STIM | ▲ Buy | Grant | 48,638 | — | 5/26/2022 | View on chart |
| MIR | ▲ Buy | Grant | 5,817 | $0 | 12/27/2021 | View on chart |
| STIM | ▲ Buy | Open Market | 15,000 | $61K | 11/22/2021 | View on chart |
| STIM | ▲ Buy | Open Market | 15,000 | $101K | 8/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
No recent news for KRMD
No new developments reported for KRMD in the past week.
No recent news for KRMD. No new developments reported for KRMD in the past week.